Daniele Galatolo,Giovanna De Michele,Gabriella Silvestri,Vincenzo Leuzzi,Carlo Casali,Olimpia Musumeci,Antonella Antenora,Guja Astrea,Melissa Barghigiani,Roberta Battini,Carla Battisti,Caterina Caputi,Ettore Cioffi,Giuseppe De Michele,Maria Teresa Dotti,Tommasina Fico,Chiara Fiorillo,Serena Galosi,Maria Lieto,Alessandro Malandrini,Marina A. B. Melone,Andrea Mignarri,Gemma Natale,Elena Pegoraro,Antonio Petrucci,Ivana Ricca,Vittorio Riso,Salvatore Rossi,Anna Rubegni,Arianna Scarlatti,Francesca Tinelli,Rosanna Trovato,Gioacchino Tedeschi,Alessandra Tessa,Alessandro Filla,Filippo Maria Santorelli

Abstract:The term hereditary ataxia (HA) refers to a heterogeneous group of neurological disorders with multiple genetic etiologies and a wide spectrum of ataxia-dominated phenotypes. Massive gene analysis in next-generation sequencing has entered the HA scenario, broadening our genetic and clinical knowledge of these conditions. In this study, we employed a targeted resequencing panel (TRP) in a large and highly heterogeneous cohort of 377 patients with a clinical diagnosis of HA, but no molecular diagnosis on routine genetic tests. We obtained a positive result (genetic diagnosis) in 33.2% of the patients, a rate significantly higher than those reported in similar studies employing TRP (average 19.4%), and in line with those performed using exome sequencing (ES, average 34.6%). Moreover, 15.6% of the patients had an uncertain molecular diagnosis. STUB1, PRKCG, and SPG7 were the most common causative genes. A comparison with published literature data showed that our panel would have identified 97% of the positive cases reported in previous TRP-based studies and 92% of those diagnosed by ES. Proper use of multigene panels, when combined with detailed phenotypic data, seems to be even more efficient than ES in clinical practice.

NGS in Hereditary Ataxia: When Rare Becomes Frequent